Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD
Launched by NOVARTIS PHARMACEUTICALS · Apr 24, 2014
Trial Information
Current as of June 15, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with active diagnosis of COPD, confirmed by spirometry documented in medical notes
- Exclusion Criteria:
- • Patients who are currently receiving other maintenance therapy (except LAMA) for COPD.
- • Patients previously prescribed Indacaterol.
About Novartis Pharmaceuticals
Novartis Pharmaceuticals is a global healthcare company dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovation, Novartis engages in the research, development, and commercialization of a broad range of therapies across various therapeutic areas, including oncology, cardiology, dermatology, and neuroscience. The company is committed to advancing scientific knowledge and patient care through clinical trials that prioritize safety and efficacy. Novartis leverages cutting-edge technology and collaborative partnerships to address unmet medical needs and deliver transformative treatments that enhance patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials